BVS vs CTKB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BVS · Bioventus$9.88 ▼ 0.70%
CTKB · Cytek Biosciences$6.12 ▼ 3.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BVS +33.3%
- CTKB +4.8%
Head to head
| Metric | BVS | CTKB |
|---|---|---|
| Price | $9.88 | $6.12 |
| Change today | ▼ 0.70% | ▼ 3.16% |
| Market cap | $676.53M | $800.40M |
| Return, 3 months | -29.5% | +37.8% |
| Return, year to date | +32.8% | +21.2% |
| Return, 1 year | +36.5% | +4.1% |
| P/E (TTM) | 12.2 | – |
| P/B | 2.8 | 2.5 |
| P/E percentile vs own 5y | 65th | 70th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +2.7% | +1.8% |
| Net profit growth (YoY) | +71.2% | -11.3% |
| Gross margin | 68.7% | 54.7% |
| Operating margin | 10.1% | -21.1% |
| Net margin | 9.8% | -39.1% |
| Return on equity | 28.2% | -23.2% |
| Analyst target vs. price | +68.7% | +18.5% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 29 | 57 |
| 30-day volatility | 75.7% | 58.9% |
| Max drawdown, 1 year | -35.3% | -42.9% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CTKB is the largest of the group by market value.
- BVS has returned the most over the past year.
- BVS is growing revenue fastest.
- BVS keeps the most profit per dollar of sales.
- CTKB has been the calmest stock over the last 30 days.